Morning Trend | GENFLEET-B weakly declines, with new research and development news becoming the biggest variable?

GENFLEET-B continued to consolidate at a low level yesterday, with extremely conservative capital flow during the session, and the sector's popularity has not seen an increase. The overall news in the innovative drug industry is weak, and the company has not had any new approvals or milestone announcements recently, leading to a natural decline in trading enthusiasm. Technically, indicators such as KDJ and MACD continue to show weakness, with key support lacking strength, and the stock price is testing new low areas for consolidation. The sector's capital is actively defensive, and the inertia of speculation is severely suppressed. It is worth noting that during previous new drug approvals or key cooperation approvals, the intraday trading often shows early movements, becoming the focus of attention in the trading community. Moving forward, it is essential to closely monitor changes in information flow and capital flow. If there is sudden positive news regarding research and development, it could become a watershed moment for short-term risk exposure. In an uncertain environment, market volatility is high. For the short term, it is recommended to maintain a light position and observe. If there is a sudden increase in intraday trading volume along with research and development progress, one can actively follow up on structural adjustment opportunities; otherwise, prioritize risk control